Literature DB >> 26940870

Two Models of Integrating Buprenorphine Treatment and Medical Staff within Formerly "Drug-Free" Outpatient Programs.

Laura Monico1, Robert P Schwartz2, Jan Gryczynski3, Kevin E O'Grady4, Shannon Gwin Mitchell3.   

Abstract

"Drug-free" outpatient programs deliver treatment to the largest number of patients of all treatment modalities in the U.S., providing a significant opportunity to expand access to medication treatments for substance use disorders. This analysis examined staff perceptions of organizational dynamics associated with the delivery of buprenorphine maintenance within three formerly "drug-free" outpatient treatment programs. Semi-structured interviews (N = 15) were conducted with counseling and medical staff, and respondents were predominantly African American (n = 11) and female (n = 12). Themes and concepts related to medical staff integration emerged through an inductive and iterative coding process using Atlas.ti qualitative analysis software. Two treatment clinics incorporated buprenorphine maintenance into their programs using a co-located model of care. Their staff generally reported greater intra-organizational discord regarding the best ways to combine medication and counseling compared to the clinic using an integrated model of care. Co-located program staff reported less communication between medical and clinical staff, which contributed to some uncertainty about proper dosing and concerns about the potential for medication diversion. Clinics that shift from "drug-free" to incorporating buprenorphine maintenance should consider which model of care they wish to adapt and how to train staff and structure staff communication.

Entities:  

Keywords:  Buprenorphine; integration; outpatient treatment; team care model; treatment staff

Mesh:

Substances:

Year:  2016        PMID: 26940870      PMCID: PMC4956482          DOI: 10.1080/02791072.2015.1130884

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  9 in total

1.  A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Authors:  Traci R Rieckmann; Anne E Kovas; Bentson H McFarland; Amanda J Abraham
Journal:  J Subst Abuse Treat       Date:  2011-08-06

2.  The Baltimore Buprenorphine Initiative: understanding the role of buprenorphine in addressing heroin addiction in an urban-based community.

Authors:  Lyn Stankiewicz Murphy; Marla T Oros; Susan G Dorsey
Journal:  J Addict Nurs       Date:  2014 Jan-Mar       Impact factor: 1.476

3.  Premature discharge from methadone treatment: patient perspectives.

Authors:  Heather Schacht Reisinger; Robert P Schwartz; Shannon Gwin Mitchell; James A Peterson; Sharon M Kelly; Kevin E O'Grady; Erica A Marrari; Barry S Brown; Michael H Agar
Journal:  J Psychoactive Drugs       Date:  2009-09

Review 4.  Findings of innovation research applied to quality management principles for health care.

Authors:  D H Gustafson; A S Hundt
Journal:  Health Care Manage Rev       Date:  1995

5.  A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans.

Authors:  Shannon Gwin Mitchell; Jan Gryczynski; Robert P Schwartz; Kevin E O'Grady; Yngvild K Olsen; Jerome H Jaffe
Journal:  Drug Alcohol Depend       Date:  2012-09-20       Impact factor: 4.492

6.  Client and counselor attitudes toward the use of medications for treatment of opioid dependence.

Authors:  Traci Rieckmann; Marilyn Daley; Bret E Fuller; Cindy P Thomas; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2006-12-08

7.  Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Hannah K Knudsen; Amanda J Abraham; J Aaron Johnson; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2009-07-03

8.  Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.

Authors:  W K Bickel; M L Stitzer; G E Bigelow; I A Liebson; D R Jasinski; R E Johnson
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

Review 9.  Prescription opioid abuse: a literature review of the clinical and economic burden in the United States.

Authors:  Roxanne Meyer; Anisha M Patel; Stacy K Rattana; Tiffany P Quock; Samir H Mody
Journal:  Popul Health Manag       Date:  2014-12       Impact factor: 2.459

  9 in total
  1 in total

1.  Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes.

Authors:  Sheryl Spithoff; Christopher Meaney; Karen Urbanoski; Katy Harrington; Bill Que; Meldon Kahan; Pamela Leece; Vivian Shehadeh; Frank Sullivan
Journal:  Can Fam Physician       Date:  2019-10       Impact factor: 3.275

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.